Type 1 Diabetes

The AJMC® Type 1 Diabetes compendium is a comprehensive resource for news and interviews about this chronic autoimmune condition.

Latest News

AJMC
Cost-Effectiveness of the MiniMed 780G System for Type 1 Diabetes

April 10th 2025

A new technology for management of diabetes is cost-effective for patients in the US with type 1 diabetes compared with traditional treatments.

counting calories | Image Credit: Andrii Symonenko-stock.adobe.com
T1D Management: Carbohydrate Counting With Technology

June 27th 2024

older person with T1D | Image Credit: dorde-stock.adobe.com
More People With T1D Are Living Into Old Age

June 19th 2024

blood sugar control concept | Image Credit: Phruetthiphong-stock.adobe.com
AYA With T1D Have Suboptimal Glucose Control

June 16th 2024

T1D icon | Image Credit: MQ-Illustrations-stock.adobe.com
Gender May Affect Whether, Why Patients With T1D Exercise

June 12th 2024

More News

insulin pen and other tools for diabetes treatment
January 25th 2023

Potential Link Between T1D Self-stigma, HbA1c in Japanese Adults

Hayden E. Klein
Though not a causal relationship, a cross-sectional study found a significant association between diabetes-related self-stigma and glycated hemoglobin (HbA1c) in Japanese adults with type 1 diabetes (T1D).
syringe and vials of drug
January 20th 2023

Teplizumab Among Clarivate's Drugs to Watch List for 2023

Hayden E. Klein
Clarivate’s “Drugs to Watch” list for 2023 mentions 15 therapeutics, including teplizumab for type 1 diabetes (T1D).
family of 2 parents and 2 children
January 14th 2023

Immediate Relatives of Patients With T1D Have Increased Individual Risk of T1D, Major Depression, ADHD

Hayden E. Klein
Individuals with a direct relative with type 1 diabetes (T1D) were 46 times more likely to have T1D and 17% more likely to have major depression, compared with individuals without.
the top 5 type 1 diabetes articles of 2022
December 26th 2022

Top 5 Most-Read T1D Articles of 2022

Hayden E. Klein
This year’s most-read type 1 diabetes (T1D) articles highlighted important trends, breakthrough technologies, and more major findings for patients with T1D.
Tom Robinson
December 17th 2022

T1D Community Helped Create T1D Index, Says JDRF's Tom Robinson

Hayden E. Klein
Tom Robinson, vice president of global access at JDRF, talks about how the community and people living with type 1 diabetes (T1D) have contributed to the T1D Index, from development to publication and going forward.
food nutrition label
December 15th 2022

Higher Fat Intake Linked to Increased Insulin Resistance, Adverse Vascular Profile in T1D

Hayden E. Klein
The study also showed daily energy intake was inversely correlated with estimated glucose disposal rate (eGDR), a marker for insulin resistance (IR).
Screenshot of Tom Robinson of JDRF during a Zoom video interview
December 9th 2022

Looking to the Future of Disease State Indexes

Hayden E. Klein
Tom Robinson, vice president of global access at JDRF, lists 3 pieces of advice for groups looking to create indexes for other conditions similar to the Type 1 Diabetes (T1D) Index.
physician taking patient's blood pressure
December 8th 2022

Parkinson Medication May Improve Blood Pressure in Teens With T1D

Hayden E. Klein
Due to the study’s small sample, further research is needed to understand the role of bromocriptine in reducing blood pressure and artery stiffness in youth with type 1 diabetes (T1D).
Tom Robinson
December 3rd 2022

JDRF's Tom Robinson Talks T1D Index's Role in Tracking Rising Prevalence

Hayden E. Klein
The first priority isn't limiting the rise in type 1 diabetes (T1D) prevalence, it's limiting the rise of missing prevalence, said Tom Robinson, vice president of global access at JDRF.
patient wearing face mask on virtual call with doctor
December 2nd 2022

Patients With COVID-19 More Likely to Experience New-Onset Diabetes

Hayden E. Klein
A review including nearly 40 million total participants showed a statistically significant positive association between infection with COVID-19 and risk of type 1 or type 2 diabetes.
Tom Robinson
November 24th 2022

T1D Index Will Be Updated Annually, JDRF’s Tom Robinson Explains

Hayden E. Klein
Updating the Type 1 Diabetes (T1D) Index each year with the latest data and literature and implementing feedback is important for at least the first few years, said Tom Robinson, vice president of global access at JDRF.
tablet with patient vitals on table
November 23rd 2022

Real-time CGM Deemed Feasible, Accurate for Managing DKA in Pediatric T1D

Hayden E. Klein
Serum bicarbonate level also did not appear to affect the accuracy of real-time continuous glucose monitoring (rtCGM) in pediatric diabetic ketoacidosis (DKA).
Tom Robinson
November 19th 2022

JDRF's Tom Robinson Expands on Policies to Ensure Implementation, Access to Key T1D Interventions

Hayden E. Klein
Get type 1 diabetes (T1D) communities involved in solving the problem and implementing T1D interventions in your country, said Tom Robinson, vice president of global access at JDRF.
FDA approval
November 18th 2022

Teplizumab Approved by FDA to Delay Type 1 Diabetes

Allison Inserro
The biologic is the first drug that aims to delay the diagnosis of type 1 diabetes.
cells
November 16th 2022

T1D Often Associated With Prevalence of Other Autoimmune Diseases

Hayden E. Klein
The 10-year follow-up in the DIACAM 1 study demonstrated a notable increase in prevalence of different types of autoimmune diseases among patients with type 1 diabetes (T1D).
Tom Robinson
November 16th 2022

JDRF's Tom Robinson Highlights Key T1D Interventions

Hayden E. Klein
While each country has a different priority when it comes to type 1 diabetes (T1D) diagnosis and treatment, there is a fairly consistent outcomes checklist across nations, said Tom Robinson, vice president of global access at JDRF.
Study Details Effects of Off-Label GLP-1 RA, SGLT2 Inhibitor Use in Type 1 Diabetes
November 9th 2022

Study Details Effects of Off-Label GLP-1 RA, SGLT2 Inhibitor Use in Type 1 Diabetes

An analysis of real-world data from a single medical center is providing insight into the effects of off-label glucagon-like peptide 1 (GLP-1) receptor agonist (RA) and sodium-glucose cotransporter-2 (SGLT2) inhibitor use in people with type 1 diabetes.
Tom Robinson
November 7th 2022

JDRF's Tom Robinson on Working With Partners to Gather Data for an Accurate T1D Index

Hayden E. Klein
Tom Robinson, vice president of global access at JDRF, talks about the data collection process in creating the Type 1 Diabetes (T1D) Index.
group of doctors and nurses, doctor writing on paper
October 29th 2022

Review Identifies Factors Associated With Increased DKA Risk in Pediatric Patients

Hayden E. Klein
Considerable research on diabetic ketoacidosis (DKA) risk has been published since the publication of a 2011 systematic review, warranting an updated analysis.
Tom Robinson
October 28th 2022

JDRF's Tom Robinson Details Research Behind T1D Index Development

Hayden E. Klein
Tom Robinson, vice president of global access at JDRF, talks about the predictive modeling exercise used to develop and refine the Type 1 Diabetes (T1D) Index.
Children in front of sunset
October 25th 2022

Serum α-Synuclein Associated With Impaired Executive Function in Patients With Obesity, T1D

Julia Bonavitacola
Serum α-synuclein was found to be increased in children with obesity and type 1 diabetes (T1D), which was linked to the impairment of executive function in these children.
Tom Robinson
October 18th 2022

JDRF's Tom Robinson Talks About Goals, Reasoning Behind T1D Index

Hayden E. Klein
According to Tom Robinson, vice president of global access at JDRF, the creation of the Type 1 Diabetes (T1D) Index was prompted by a lack of basic data on the condition, such as how many people are living with and affected by T1D.
anxiety
October 11th 2022

Mental Health Disparities Observed in People With Diabetes Across Europe

Connor Iapoce
People with diabetes in Italy and the United Kingdom reported the highest rates of anxiety at 63% and 51%, respectively.
Tom Robinson, JDRF
October 7th 2022

JDRF's Tom Robinson Explains How to Use the T1D Index

Hayden E. Klein
Tom Robinson, vice president of global access at JDRF, explains how to navigate the Type 1 Diabetes (T1D) Index and what data can be pulled from it.
closed loop insulin delivery system
October 4th 2022

Bionic Pancreas More Effective at Managing T1D Compared With Standard Insulin Delivery

Hayden E. Klein
The bionic pancreas uses algorithms to continually adjust insulin doses based on the user’s needs, requiring less user input compared with other existing artificial pancreas technologies.
digital world map
September 29th 2022

JDRF Launches Global T1D Index

Hayden E. Klein
The Type 1 Diabetes (T1D) Index measures global T1D prevalence and provides other statistics and estimates related to the autoimmune condition.
globe
September 24th 2022

Number of T1D Cases Expected to Double Worldwide by 2040

Hayden E. Klein
In 2040, researchers predict between 13.5 and 17.4 million type 1 diabetes (T1D) cases globally, reflecting a 60% to 107% increase in cases compared with 2021.
What We're Reading
September 23rd 2022

What We’re Reading: Deal Reached for FDA User Fee Programs; Link Between COVID-19, T1D; DOJ Protects VA Employees Providing Abortions

AJMC Staff
A deal was reached to renew 5-year FDA user fee programs; children and adolescents with COVID-19 had a 60% increased risk of developing type 1 diabetes (T1D); states cannot penalize Department of Veterans Affairs (VA) employees for facilitating abortions permitted by federal law.
group of children
September 15th 2022

AHCL Insulin Delivery Linked to Better QOL, Metabolic Control in Children With T1D

Hayden E. Klein
Children and adolescents with type 1 diabetes (T1D) saw improved quality of life (QOL) and metabolic control when using an advanced hybrid closed-loop (AHCL) insulin delivery method vs conventional therapy.
nurse injecting child patient with medicine
September 10th 2022

Subcutaneous Insulin Linked to Reduced Hospital Costs, LOS in Children With Mild DKA

Hayden E. Klein
Treating children with mild diabetic ketoacidosis (DKA) using subcutaneous (SC) insulin aspart was linked to lower hospital costs and better efficacy of DKA management, compared with using intravenous (IV) insulin.
<123456789>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo